APA (7th ed.) Citation

M, B., B, d. G., T, G. V., NM, v. S., HE, d. M., & A, S. (2026). Product- and schedule-specific vaccine effectiveness against invasive Haemophilus influenzae serotype b (Hib) disease, The Netherlands, 2005 to 2023. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 31(19), . https://doi.org/10.2807/1560-7917.ES.2026.31.19.2500699

Chicago Style (17th ed.) Citation

M, Bertran, de Gier B, Garcia Vilaplana T, van Sorge NM, de Melker HE, and Steens A. "Product- and Schedule-specific Vaccine Effectiveness Against Invasive Haemophilus Influenzae Serotype B (Hib) Disease, The Netherlands, 2005 to 2023." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 31, no. 19 (2026). https://doi.org/10.2807/1560-7917.ES.2026.31.19.2500699.

MLA (9th ed.) Citation

M, Bertran, et al. "Product- and Schedule-specific Vaccine Effectiveness Against Invasive Haemophilus Influenzae Serotype B (Hib) Disease, The Netherlands, 2005 to 2023." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 31, no. 19, 2026, https://doi.org/10.2807/1560-7917.ES.2026.31.19.2500699.